This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Efficacy and Safety of Ainuovirine Treating With AIDS Patients

Sponsored by Guangzhou 8th People's Hospital

About this trial

Last updated 3 years ago

Study ID

X220314682

Status

Recruiting

Type

Observational

Placebo

No

Accepting

18-75 Years
18 to 60 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 3 years ago

What is this trial about?

Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical studies show that Ainuovirine is safe and potent, it solves the problem from the first-generation NNRTIs such as Efavirenz with large side effects and the second-generation like Rilpivirine not suitable for high viral load, but there are no relevant data or reports on the efficacy and safety of Ainuovirine in HIV-infected patients in China so far. This project aims to explore the efficacy and safety of ART regimens containing Ainuovirine for HIV-infected patients in real clinical environment, in further to guide clinical application.

What are the participation requirements?

Yes

Inclusion Criteria

Diagnosis of HIV infection 18-60 years old Patients who are prescribed to take Ainuovirine regimen . Sign informed consent

No

Exclusion Criteria

1. Patients who are participating in other interventional clinical trials; 2. Patients who previously participated in the ACC007 study.

Locations

Location

Status

Recruiting